| Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course (NCT01086683) | Danish Cancer Society | 2004-05-01 |
| Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness (NCT00088023) | Spectrum Pharmaceuticals, Inc | 2004-03-01 |
| Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors (NCT02171663) | Boehringer Ingelheim | 2004-03-01 |
| PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy (NCT00388336) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-02-01 |
| A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia (NCT00117039) | Amgen | 2004-01-01 |
| Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma (NCT00078637) | Eisai Inc. | 2004-01-01 |
| A Trial Of SU14813 In Patients With Advanced Solid Malignancies (NCT00982267) | Pfizer | 2003-12-01 |
| Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced (NCT00210002) | Institut Claudius Regaud | 2003-11-01 |
| REST: Reducing End-of-Life Symptoms With Touch (NCT00065195) | National Center for Complementary and Integrative Health (NCCIH) | 2003-11-01 |
| Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors (NCT02171637) | Boehringer Ingelheim | 2003-11-01 |
| Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients (NCT00578630) | Memorial Sloan Kettering Cancer Center | 2003-10-14 |
| Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members (NCT00071045) | National Heart, Lung, and Blood Institute (NHLBI) | 2003-10-08 |
| Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors (NCT00095160) | Masonic Cancer Center, University of Minnesota | 2003-10-01 |
| Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus) (NCT00065234) | National Center for Complementary and Integrative Health (NCCIH) | 2003-09-01 |
| A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy (NCT00216541) | Janssen-Cilag B.V. | 2003-08-01 |
| Studying Normal Breast Tissue and Cancer Risk (NCT00341692) | National Cancer Institute (NCI) | 2003-04-07 |
| A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors (NCT00057473) | Bristol-Myers Squibb | 2003-02-01 |
| STA-4783 and Paclitaxel for Treatment of Solid Tumors (NCT00088114) | Synta Pharmaceuticals Corp. | 2003-01-01 |
| Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors (NCT00104286) | SGX Pharmaceuticals, Inc. | 2003-01-01 |
| STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea (NCT00050635) | Novartis Pharmaceuticals | 2002-12-01 |
| A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer (NCT00050427) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-12-01 |
| Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein (NCT00048880) | National Cancer Institute (NCI) | 2002-11-05 |
| Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy (NCT00120705) | Amgen | 2002-11-01 |
| Depsipeptide to Treat Thyroid and Other Advanced Cancers (NCT00048334) | National Cancer Institute (NCI) | 2002-10-26 |
| Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer (NCT00046540) | INSYS Therapeutics Inc | 2002-10-01 |
| A Study of Trabectedin in Patients With Advanced Ovarian Cancer (NCT00050414) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-10-01 |
| Marijuana for Cancer Pain (NCT00046709) | Center for Medicinal Cannabis Research | 2002-09-01 |
| Collection of Blood, Bone Marrow, Tumor or Tissue Samples (NCT00043615) | National Cancer Institute (NCI) | 2002-07-29 |
| D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients (NCT00047476) | Celgene Corporation | 2002-06-01 |
| Darbepoetin Alfa and Anemia of Cancer (NCT00989092) | Amgen | 2002-05-01 |
| Meaning-Centered Psychotherapy in Advanced Cancer (NCT00067288) | National Center for Complementary and Integrative Health (NCCIH) | 2002-05-01 |
| Constipation in Pediatric Cancer Patients Receiving Vinca Alkaloids or Narcotics (NCT00032682) | National Institutes of Health Clinical Center (CC) | 2002-03-01 |
| A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies (NCT00055263) | Novacea | 2002-03-01 |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer (NCT00384891) | Medical Enterprises Europe B.V. | 2002-02-01 |
| Age Gene/Environment Susceptibility Reykjavik Study (NCT03269656) | Icelandic Heart Association | 2002-01-01 |
| Vitamin D Levels and Survival in Cancer Patients (NCT03266887) | Icelandic Heart Association | 2002-01-01 |
| Anemia in Patients With a Non-Myeloid Malignancy (NCT00038064) | Amgen | 2002-01-01 |
| Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy (NCT00349830) | Stanford University | 2002-01-01 |
| Developmental Study on Fatigue in Cancer (NCT00034450) | National Center for Complementary and Integrative Health (NCCIH) | 2002-01-01 |
| Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors (NCT00027027) | Genentech, Inc. | 2001-11-01 |
| Study of Noni in Cancer Patients (NCT00033878) | National Center for Complementary and Integrative Health (NCCIH) | 2001-11-01 |
| A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors (NCT00030173) | Bristol-Myers Squibb | 2001-10-01 |
| Socioeconomic Influences on Complementary and Alternative Medicine Use in Cancer Treatment (NCT00087932) | National Center for Complementary and Integrative Health (NCCIH) | 2001-09-01 |
| A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients (NCT00042328) | Baylor College of Medicine | 2001-08-01 |
| Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED) (NCT00040547) | Merck Sharp & Dohme LLC | 2001-06-01 |
| A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer (NCT00165451) | Dana-Farber Cancer Institute | 2001-06-01 |
| Kanglaite Injection Phase I Study (NCT00031031) | KangLaiTe USA | 2001-06-01 |
| A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors. (NCT00046696) | Genzyme, a Sanofi Company | 2001-05-01 |
| Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors (NCT00024661) | INSYS Therapeutics Inc | 2001-03-01 |
| Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies (NCT00024648) | INSYS Therapeutics Inc | 2001-03-01 |
| Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days (NCT00024674) | INSYS Therapeutics Inc | 2001-02-01 |
| Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED) (NCT00040534) | Merck Sharp & Dohme LLC | 2001-01-01 |
| Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses (NCT00024687) | INSYS Therapeutics Inc | 2000-11-01 |
| Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients (NCT00041782) | M.D. Anderson Cancer Center | 2000-10-01 |
| A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies (NCT00046423) | Celgene Corporation | 2000-04-01 |
| Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance (NCT00219791) | BTG International Inc. | 2000-01-01 |
| Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia (NCT00037791) | Pfizer | 1999-12-01 |
| Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers (NCT00740922) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1999-07-01 |
| A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer (NCT02721641) | Hoffmann-La Roche | 1999-06-01 |
| 5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer (NCT00359606) | City of Hope Medical Center | 1999-04-01 |
| Prospective Study of Health in Runners and Walkers (NCT00005494) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-06-01 |
| A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors (NCT00001579) | National Cancer Institute (NCI) | 1997-06-01 |
| Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors (NCT00001668) | National Institute of Neurological Disorders and Stroke (NINDS) | 1997-04-01 |
| Cord Blood Stem Cell Transplantation Study (COBLT) (NCT00000603) | National Heart, Lung, and Blood Institute (NHLBI) | 1996-09-01 |
| A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors (NCT00001495) | National Cancer Institute (NCI) | 1995-11-01 |
| A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients (NCT00001449) | National Cancer Institute (NCI) | 1995-09-01 |
| Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients (NCT00169845) | Laval University | 1994-10-01 |
| Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy (NCT00001387) | National Cancer Institute (NCI) | 1994-09-01 |
| The European Prospective Investigation Into Cancer in Norfolk Prospective Population Study (NCT03424668) | University of Cambridge | 1992-01-01 |
| Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia (NCT00270049) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1990-11-01 |
| Dietary Patterns and Health Outcomes (Cardiovascular, Metabolic, Endocrine, Neurological, Skeletal Muscular, Cancer) (NCT03328546) | Harvard School of Public Health (HSPH) | 1989-01-01 |
| The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors (NCT00001189) | National Cancer Institute (NCI) | 1983-12-01 |
| Study Evaluating MST-997 in Advanced Malignant Solid Tumors (NCT00088647) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC (NCT06841874) | Nuvation Bio Inc. | |
| A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors (NCT00225550) | Adherex Technologies, Inc. | |
| A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection (NCT00264446) | Adherex Technologies, Inc. | |
| Measuring Alterations of DNA in Human Blood (NCT00178308) | University of Rochester | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I (NCT02254915) | Medical Enterprises Europe B.V. | |
| A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug (NCT00269997) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study Evaluating MST-997 in Advanced Malignant Solid Tumors (NCT00277836) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity (NCT00481559) | BTG International Inc. | |
| Vorasidenib Expanded Access Program (NCT05592743) | Servier | |
| A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent (NCT00264433) | Adherex Technologies, Inc. | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC (NCT02824094) | Pfizer | |